Evolution by innovation: improving TCR-Ts for solid tumors

How can TCR-based therapeutics learn from the field’s experiences with CAR-T, and better tackle the complex challenges posed by solid tumors? Roisin McGuigan, Editor, Immuno–Oncology Insights, speaks to Dolores Schendel, Chief Scientific Officer, Medigene, about current and future applications of TCR therapies in solid cancers.  

Please enter your email to access content Read now